SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
The Federal Reserve terminated enforcement actions against Allegiant United Holdings, LLC, Nano Financial Holdings, Inc., and Nano Banc. The termination followed the resolution of …
Microbot Medical Inc. received a patent for an adaptor from the CIPO, expanding its intellectual property portfolio to 45 issued patents and 48 applications, bolstering its strateg…
Intellia has completed its field organization deployment and strengthened engagement with payers for its HAE treatment lonvo-z. The stock is reacting positively to the data ahead o…
Filana announced the FDA lifted the clinical hold on simufilam in Q3, expecting patient screening to begin by Q1 2027; the company reported $47.0 million in cash with R&D expenses …
Dyne Therapeutics reported Q3 financials and announced its z-rostudirsen BLA received FDA priority review with a PDUFA date of Jan 2027, marking a critical regulatory step for the …
Palvella Therapeutics announced FDA acceptance of its QTORIN rapamycin application with a focused launch plan ahead of a February 28, 2027 priority review deadline. The development…
Middleby Corporation signed a Ninth Amended and Restated Credit Agreement with banks including Bank of America and JPMorgan Chase, dated November 4, 2026. The terms reflect a stand…
Tenaya announced regulatory biomarker for heart disease and provided business updates ahead of quarterly data. The stock is expected to react to key interim trial results and pivot…
Mineralys reported 46% of patients met AHA guidelines in Launch-HTN at Week 12. The positive data bolsters investor confidence ahead of a key FDA decision for its hypertension drug…
Aircastle Limited announced it will discontinue voluntary SEC filings following the maturity of its bond debt in May 2026, marking its final Form 10-Q filing on November 9.
Oncolytics Biotech announced positive translational data from SITC 2026 showing that its oncolytic virus pelareorep, combined with a checkpoint inhibitor, increases HPV-16-specific…
CDT Equity Inc. amended its certificate of incorporation to increase authorized capital stock to 251 million shares and set an effective date of November 5, 2026, for a one-for-twe…
Royale Energy, Inc. commenced trading on the OTCQB Venture Market effective November 4, 2026, following the restoration of its SEC reporting compliance, a significant milestone in …
Clene submitted an FDA NDA for ALS drug CNM-Au8 and expects cash runway to improve by leveraging capital from a 2026 financing, signaling progress for this clinical-stage biopharma…
NewAmsterdam Pharma received European Commission approval for Ubeslo and Evlarco, marking the first regulatory approval of its drug obicetrapib. The update also reported strategic …
uniQure reports 2026 Q3 results; FDA granted Priority Review for AMT-130 with a PDUFA date of May 1, 2027; company expects cash runway into 2030.
MoonLake submitted a BLA for sonelokimab to treat hidradenitis suppurativa, while reporting positive Phase 3 PsA results late in the quarter.
International Flavors & Fragrances Inc. updated its bylaws to include amendments as of October 28, 2026, and extended the meetings section provisions.
Enova International filed an exhibit on Form 8-K detailing delinquency metrics for OnDeck term loans, indicating increases in past-due balances and change in trends across specific…
Chilean Cobalt Corp. and NeoRe SpA have amended their earn-in agreement with the option period extended to Fiscal year 27 and the NSR tier terms confirmed.